Ribavirin and Hearing loss - a phase IV clinical study of FDA data
Summary:
Hearing loss is reported as a side effect among people who take Ribavirin (ribavirin), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Pegasys, and have High blood pressure.
The phase IV clinical study analyzes which people have Hearing loss when taking Ribavirin. It is created by eHealthMe based on reports of 78,378 people who have side effects when taking Ribavirin from the FDA, and is updated regularly.
What is Ribavirin?
Ribavirin has active ingredients of ribavirin. It is often used in hepatitis c. eHealthMe is studying from 78,532 Ribavirin users. Check the latest studies of Ribavirin.
What is Hearing loss?
Hearing loss is found to be associated with 1,351 drugs and 2,377 conditions by eHealthMe. Check the latest studies of Hearing loss.
78,378 people reported to have side effects when taking Ribavirin.
Among them, 132 people (0.17%) have Hearing loss.
Among these 132 people:
How long have people been on Ribavirin when they have Hearing loss? *
What is the gender of people who have Hearing loss when taking Ribavirin? *
What is the age of people who have Hearing loss when taking Ribavirin? *
What are other drugs people take besides Ribavirin? *
What are other side effects people have besides Hearing loss? *
What are the existing conditions these people have? *
* Approximation only. Some reports may have incomplete information.
Do you take Ribavirin and have Hearing loss?
- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Ribavirin:
- Ribavirin (78,532 reports)
Hearing loss treatments and more:
- Hearing loss (30,352 reports)
How severe was Hearing loss and when was it recovered:
Expand to all the drugs that have ingredients of ribavirin:
- Hearing loss and drugs with ingredients of ribavirin (246 reports)
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Ribavirin:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Hearing loss:
- Hearing loss (1,351 drugs)
Browse all the conditions that are associated with Hearing loss:
- Hearing loss (2,377 conditions)
Related publications that referenced our studies
- Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
- Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
- Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
- Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on ribavirin (the active ingredients of Ribavirin) and Ribavirin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Sitagliptin Phosphate and Lexapro - 4 seconds ago
- Could Prochlorperazine Maleate cause Local Swelling? - 11 seconds ago
- Could Phenergan cause Ventricular Dysfunction? - 16 seconds ago
- Drug interactions of Oracea and Singulair - 18 seconds ago
- Could Nitro-Dur cause Back Pain? - 18 seconds ago
- Stress And Anxiety and Blood Bilirubin Increased - 22 seconds ago
- Could Xolair cause Nerve Compression? - 22 seconds ago
- Could Evista cause Vaginal Bleeding Between Periods? - 31 seconds ago
- Drug interactions of Naprosyn and Simvastatin - 31 seconds ago
- Could Lactulose cause General Physical Health Deterioration? - 37 seconds ago